PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With "central support," more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated. RECENT FINDINGS: The increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included. Our data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.

3rd Department of Medicine Department of Endocrinology and Metabolism of the 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Cantonal Hospital Zenica Zenica Bosnia and Herzegovina

Centre for Cardiovascular Surgery and Transplantation Brno Czech Republic

Clinic for Endocrinology Diabetes and Metabolic Diseases Belgrade Serbia

Coordination Center for Familial Hyperlipidemias Slovak Medical University Bratislava Slovakia

Department of Internal Medicine Faculty of Medicine University of Debrecen Debrecen Hungary

Faculty of Medicine University of Belgrade Belgrade Serbia

Head of Department of Ischemic Heart Disease and Atherosclerosis Republican Specialised Center of Cardiology Tashkent Uzbekistan

Institute of Epidemiology School of Medicine Comenius University Bratislava Slovakia

Institute of Nutrition Faculty of Nursing and Health Professional Studies and Coordination Centre for Familial Hyperlipoproteinemias Slovak Medical University in Bratislava Bratislava Slovakia

Latvian Research Institute of Cardiology Faculty of Medicine University of Latvia Riga Latvia

Medical Faculty Masaryk University Brno Czech Republic

National Cardiology Research Center Moscow Russia

National Registry Coordinator in Ukraine Kiev Ukraine

Paul Stradins Clinical University Hospital Riga Latvia

Vilnius University Faculty of Medicine Vilnius Lithuania

Vilnius University Hospital Santaros Klinikos Vilnius Lithuania

Zobrazit více v PubMed

Navar-Boggan AM, Peterson ED, D’Agostino RB, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131:451–458. doi: 10.1161/CIRCULATIONAHA.114.012477. PubMed DOI PMC

Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–3490. doi: 10.1093/eurheartj/eht273. PubMed DOI PMC

Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795–1803. doi: 10.1172/JCI200318925. PubMed DOI PMC

Huijgen R, Kindt I, Fouchier SW, et al. Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat. 2010;31:752–760. doi: 10.1002/humu.21258. PubMed DOI

Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, Li KW, Drenos F, Karpe F, Neil HAW, Descamps OS, Langenberg C, Lench N, Kivimaki M, Whittaker J, Hingorani AD, Kumari M, Humphries SE. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381:1293–1301. doi: 10.1016/S0140-6736(12)62127-8. PubMed DOI

Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407–420. doi: 10.1093/aje/kwh236. PubMed DOI

Descamps OS, Gilbeau JP, Leysen X, van Leuven F, Heller FR. Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia. Eur J Clin Investig. 2001;31:958–965. doi: 10.1046/j.1365-2362.2001.00915.x. PubMed DOI

Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008;11:26–35. PubMed

Besseling J, Kindt I, Hof M, Kastelein JJP, Hutten BA, Hovingh GK. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis. 2014;233:219–223. doi: 10.1016/j.atherosclerosis.2013.12.020. PubMed DOI

Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853. doi: 10.1093/eurheartj/ehq386. PubMed DOI PMC

Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256:482–490. doi: 10.1111/j.1365-2796.2004.01405.x. PubMed DOI

Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis. 2011;214:129–138. doi: 10.1016/j.atherosclerosis.2010.10.008. PubMed DOI

Robinson JG, Goldberg AC. National Lipid Association Expert Panel on familial hypercholesterolemia. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S18–S29. doi: 10.1016/j.jacl.2011.03.451. PubMed DOI

Ademi Z, Watts GF, Pang J, Sijbrands EJG, van Bockxmeer FM, O'Leary P, Geelhoed E, Liew D. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8:390–400. doi: 10.1016/j.jacl.2014.05.008. PubMed DOI

Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJP, Sijbrands EJG. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. doi: 10.1136/bmj.a2423. PubMed DOI PMC

Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124:2202–2207. doi: 10.1161/CIRCULATIONAHA.111.042523. PubMed DOI

Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084–1091. doi: 10.1016/S0002-9149(02)02774-1. PubMed DOI

Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP IIIgoals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80(5):587–595. doi: 10.4065/80.5.587. PubMed DOI

Stephenson SH, Larrinaga-Shum S, Hopkins PN. Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia. J Clin Lipidol. 2009;3(2):94–100. doi: 10.1016/j.jacl.2009.02.004. PubMed DOI

Hammond E, Watts GF, Rubinstein Y, Farid W, Livingston M, Knowles JW, Lochmüller H, Bellgard M, Dawkins HJS. Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc. 2013;11:134–139. doi: 10.1111/1744-1609.12023. PubMed DOI

Freiberger T, Vrablík M. Early diagnosis of familial hypercholesterolemia in Czech Republic in pursuance of MedPed project. Vnitr Lek. 2015;61(11):942–945. PubMed

Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000;321:148. doi: 10.1136/bmj.321.7254.148. PubMed DOI PMC

Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelein JJP. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet. 2012;5:354–359. doi: 10.1161/CIRCGENETICS.111.962456. PubMed DOI

Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5. PubMed DOI PMC

Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014;65:417–431. doi: 10.1146/annurev-med-022613-090402. PubMed DOI

Raal F, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA. Trial evaluating evolocumab, a PCSK9 antibody, in patients with homozygous FH (TESLA): results of the randomized, double-blind placebo-controlled trial. Atherosclerosis. 2014;235:e12. doi: 10.1016/j.atherosclerosis.2014.05.004. DOI

Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program) Am J Cardiol. 2017;119(1):40–46. doi: 10.1016/j.amjcard.2016.09.010. PubMed DOI

Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016;57(6):1086–1096. doi: 10.1194/jlr.P065334. PubMed DOI PMC

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk) Circulation. 2018;137(4):338–350. doi: 10.1161/CIRCULATIONAHA.117.032235. PubMed DOI

Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–1819. doi: 10.1056/NEJMoa1316222. PubMed DOI

Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–689. doi: 10.1016/j.ahj.2014.07.028. PubMed DOI

Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM, CLEAR Harmony Trial Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032. doi: 10.1056/NEJMoa1803917. PubMed DOI

Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37(17):1384–1394. doi: 10.1093/eurheartj/ehw028. PubMed DOI

Latkovskis G, Saripo V, Gilis D, Nesterovics G, Upena-Roze A, Erglis A. Latvian registry of familial hypercholesterolemia: the first report of three-year results. Atherosclerosis. 2018;277:347–354. doi: 10.1016/j.atherosclerosis.2018.06.011. PubMed DOI

Lehrman MA, Schneider WJ, Brown MS, et al. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem. 1987;262(1):401–410. PubMed

Abifadel M, Rabès JP, Jambart S, et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat. 2009;30(7):E682–E691. doi: 10.1002/humu.21002. PubMed DOI

Watts GF, Ding PY, George P, et al. Translational research for improving the care of familial hypercholesterolemia: the “Ten Countries Study” and beyond. J Atheroscler Thromb. 2016;23:891–900. doi: 10.5551/jat.35949. PubMed DOI PMC

Pang J, Hu M, Lin J, Miida T, Nawawi HM, Park JE, Wu X, Ramli AS, Kim NT, Kwok S, Gonzalez-Santos LE, Su TC, Truong TH, Soran H, Yamashita S, Tomlinson B, Watts GF. An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the “Ten Countries Study”. BMJ Open. 2017;7:e017817. doi: 10.1136/bmjopen-2017-017817. PubMed DOI PMC

EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Atherosclerosis. 2018;277:234–255. doi: 10.1016/j.atherosclerosis.2018.08.051. PubMed DOI

Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia

Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias

Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics

Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters